These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19351401)

  • 1. Oral cholera vaccine use in Zanzibar: socioeconomic and behavioural features affecting demand and acceptance.
    Schaetti C; Hutubessy R; Ali SM; Pach A; Weiss MG; Chaignat CL; Khatib AM
    BMC Public Health; 2009 Apr; 9():99. PubMed ID: 19351401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sociocultural determinants of anticipated oral cholera vaccine acceptance in three African settings: a meta-analytic approach.
    Sundaram N; Schaetti C; Merten S; Schindler C; Ali SM; Nyambedha EO; Lapika B; Chaignat CL; Hutubessy R; Weiss MG
    BMC Public Health; 2016 Jan; 16():36. PubMed ID: 26762151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Social and cultural determinants of anticipated acceptance of an oral cholera vaccine prior to a mass vaccination campaign in Zanzibar.
    Schaetti C; Chaignat CL; Hutubessy R; Khatib AM; Ali SM; Schindler C; Weiss MG
    Hum Vaccin; 2011 Dec; 7(12):1299-308. PubMed ID: 22108036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The case for reactive mass oral cholera vaccinations.
    Reyburn R; Deen JL; Grais RF; Bhattacharya SK; Sur D; Lopez AL; Jiddawi MS; Clemens JD; von Seidlein L
    PLoS Negl Trop Dis; 2011 Jan; 5(1):e952. PubMed ID: 21283614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rapid qualitative assessment of oral cholera vaccine anticipated acceptability in a context of resistance towards cholera intervention in Nampula, Mozambique.
    Démolis R; Botão C; Heyerdahl LW; Gessner BD; Cavailler P; Sinai C; Magaço A; Le Gargasson JB; Mengel M; Guillermet E
    Vaccine; 2018 Oct; 36(44):6497-6505. PubMed ID: 29174106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local perceptions of cholera and anticipated vaccine acceptance in Katanga province, Democratic Republic of Congo.
    Merten S; Schaetti C; Manianga C; Lapika B; Chaignat CL; Hutubessy R; Weiss MG
    BMC Public Health; 2013 Jan; 13():60. PubMed ID: 23339647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar.
    Schaetti C; Weiss MG; Ali SM; Chaignat CL; Khatib AM; Reyburn R; Duintjer Tebbens RJ; Hutubessy R
    PLoS Negl Trop Dis; 2012; 6(10):e1844. PubMed ID: 23056660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving community coverage of oral cholera mass vaccination campaigns: lessons learned in Zanzibar.
    Schaetti C; Ali SM; Chaignat CL; Khatib AM; Hutubessy R; Weiss MG
    PLoS One; 2012; 7(7):e41527. PubMed ID: 22844489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Social and cultural determinants of oral cholera vaccine uptake in Zanzibar.
    Schaetti C; Ali SM; Hutubessy R; Khatib AM; Chaignat CL; Weiss MG
    Hum Vaccin Immunother; 2012 Sep; 8(9):1223-9. PubMed ID: 22894965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Social and cultural features of cholera and shigellosis in peri-urban and rural communities of Zanzibar.
    Schaetti C; Khatib AM; Ali SM; Hutubessy R; Chaignat CL; Weiss MG
    BMC Infect Dis; 2010 Nov; 10():339. PubMed ID: 21110853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model.
    Kar SK; Sah B; Patnaik B; Kim YH; Kerketta AS; Shin S; Rath SB; Ali M; Mogasale V; Khuntia HK; Bhattachan A; You YA; Puri MK; Lopez AL; Maskery B; Nair GB; Clemens JD; Wierzba TF
    PLoS Negl Trop Dis; 2014 Feb; 8(2):e2629. PubMed ID: 24516675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study.
    Khatib AM; Ali M; von Seidlein L; Kim DR; Hashim R; Reyburn R; Ley B; Thriemer K; Enwere G; Hutubessy R; Aguado MT; Kieny MP; Lopez AL; Wierzba TF; Ali SM; Saleh AA; Mukhopadhyay AK; Clemens J; Jiddawi MS; Deen J
    Lancet Infect Dis; 2012 Nov; 12(11):837-44. PubMed ID: 22954655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and acceptability of oral cholera vaccine mass vaccination campaign in response to an outbreak and floods in Malawi.
    Msyamboza KP; M'bang'ombe M; Hausi H; Chijuwa A; Nkukumila V; Kubwalo HW; Desai S; Pezzoli L; Legros D
    Pan Afr Med J; 2016; 23():203. PubMed ID: 27347292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012.
    Luquero FJ; Grout L; Ciglenecki I; Sakoba K; Traore B; Heile M; Dialo AA; Itama C; Serafini M; Legros D; Grais RF
    PLoS Negl Trop Dis; 2013; 7(10):e2465. PubMed ID: 24147164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral cholera vaccine coverage during a preventive door-to-door mass vaccination campaign in Nampula, Mozambique.
    Semá Baltazar C; Rafael F; Langa JPM; Chicumbe S; Cavailler P; Gessner BD; Pezzoli L; Barata A; Zaina D; Inguane DL; Mengel MA; Munier A
    PLoS One; 2018; 13(10):e0198592. PubMed ID: 30281604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and costs of a targeted cholera vaccination campaign in Ethiopia.
    Teshome S; Desai S; Kim JH; Belay D; Mogasale V
    Hum Vaccin Immunother; 2018; 14(10):2427-2433. PubMed ID: 29648523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral vaccines for preventing cholera.
    Sinclair D; Abba K; Zaman K; Qadri F; Graves PM
    Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD008603. PubMed ID: 21412922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Cholera Vaccination Delivery Cost in Low- and Middle-Income Countries: An Analysis Based on Systematic Review.
    Mogasale V; Ramani E; Wee H; Kim JH
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005124. PubMed ID: 27930668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial.
    Qadri F; Ali M; Chowdhury F; Khan AI; Saha A; Khan IA; Begum YA; Bhuiyan TR; Chowdhury MI; Uddin MJ; Khan JAM; Chowdhury AI; Rahman A; Siddique SA; Asaduzzaman M; Akter A; Khan A; Ae You Y; Siddik AU; Saha NC; Kabir A; Riaz BK; Biswas SK; Begum F; Unicomb L; Luby SP; Cravioto A; Clemens JD
    Lancet; 2015 Oct; 386(10001):1362-1371. PubMed ID: 26164097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.